MedPath

Serum Calprotectin in Surgical Septic Patients

Recruiting
Conditions
Infection, Intraabdominal
Sepsis Abdominal
Biomarker
Interventions
Diagnostic Test: serum calprotectin
Registration Number
NCT06614088
Lead Sponsor
Azienda Ospedaliero, Universitaria Pisana
Brief Summary

To early evaluate the serum levels of calprotectin in patients suffering from intra-abdominal sepsis requiring a surgical treatment. The research project aims to investigate the role of serum calprotectin in the diagnosis of sepsis and to establish whether its level significantly correlates with different degree of disease severity and with short and long-term outcomes. If these associations were confirmed, serum calprotectin would represent an easily and rapidly detectable biomarker able to predict the severity of sepsis.

Detailed Description

Inclusion criteria are age\>18 years; diagnosis of upper/lower gastro-intestinal perforation, intestinal occlusion, acute cholecystitis, acute appendicitis or intra-abdominal sepsis.

Enrolled patients will be divided in two groups according to the Calgary PIRO (CPIRO) score evaluation: group A includes patients with CPIRO score \</= 2 and represents patient with mild form of intra-abdominal sepsis while group B includes patients with CPIRO score \>/= 3, therefore representing patients with more severe systemic forms. The control group (group C) will be made by elective surgical adult patients.

A blood sample will be collected in sample tubes without anticoagulant from all the eligible patients at admission. After centrifugation, the serum will be stored at -80°C until analysis. The serum level of calprotectin will be measured using a commercially available ELISA Kit based on polyclonal antibodies, according to the manufacturer instruction and fully blinded to any clinical data of the patients or controls.

To our knowledge, this is going to be the first study comparing the levels of serum calprotectin in a large cohort of surgical patients with different degree of intra-abdominal sepsis.

Our primary outcome is to determine whether the serum calprotectin level at the admission is increased in septic patients compared to the control group. We will correlate serum calprotectin level with PCT levels, to check which is the most accurate for the detection of sepsis. Our secondary outcome is to analyze if serum calprotectin level at admission correlates with the clinical severity of sepsis, evaluated trough the CPIRO score. Finally, we will verify if calprotectin level at admission is predictive of short and long-term morbidity and mortality, need for ICU admission and invasive/non-invasive post-operative reinterventions.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • diagnosis of upper/lower gastro-intestinal perforation
  • diagnosis of intestinal occlusion
  • diagnosis of acute cholecystitis
  • diagnosis of complicated acute appendicitis
  • radiological diagnosis of intra-abdominal sepsis
Exclusion Criteria
  • recent (<3 months) surgery
  • recent (<3 months) trauma
  • diagnosis of acute pancreatitis
  • diagnosis of burn

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Group Aserum calprotectinEligible patients with CPIRO 0-2
Group Bserum calprotectinEligible patients with CPIRO \>3
Group Cserum calprotectinControl group (elective surgical patients without any source of intra-abdominal infection)
Primary Outcome Measures
NameTimeMethod
Sepsis detectionadmission

We'll measure the serum calprotectin level in enrolled patients of the two groups (group A and B) and in patients of the control group.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Azienda Ospedaliero Universitaria Pisana (AOUP)

🇮🇹

Pisa, Italy

© Copyright 2025. All Rights Reserved by MedPath